One-Shot gene therapy tested in boys with devastating muscle disease
NCT ID NCT07160634
Summary
This late-stage trial is testing whether a single intravenous dose of an experimental gene therapy, called SGT-003, can help boys with Duchenne muscular dystrophy (DMD) maintain their ability to walk and perform other physical tasks. The study will involve 80 boys who can still walk and will compare the therapy to a placebo. Participants will be monitored for at least 5 years to see how well the treatment works and to check for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Children's Hospital
RECRUITINGVancouver, British Columbia, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Children's Hospital of Westmead
RECRUITINGSydney, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.